article thumbnail

FLJ Group Limited Entered into a Definitive Agreement to Acquire Alpha Mind Technology Limited

Benzinga

Upon the closing of the Acquisition, Alpha Mind will become a wholly-owned subsidiary of the Company. The Notes have a maturity of 90 days from the closing date, and will be secured by all of the issued and outstanding equity of the Target Company and all of the assets of the Target Company and its subsidiaries. SHANGHAI, China, Nov.

Alpha 40
article thumbnail

FLJ Group Limited Announces Completion of Acquisition of Alpha Mind Technology Limited and Termination of the Lianlian Acquisition

Benzinga

28, 2023 (GLOBE NEWSWIRE) -- FLJ Group Limited (NASDAQ: FLJ ) (the "Company"), today announced the completion of the transaction previously announced on November 22, 2023 between Alpha Mind Technology Limited (the "Target Company" or "Alpha Mind"), the Target Company's shareholders (the "Sellers") and the Company (the "Transaction").

Alpha 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Apartment Rental Platform FLJ Group Shares Are Rocketing Today

Benzinga

FLJ Group Ltd (NASDAQ: FLJ ) shares are trading higher by 93% after the company disclosed the completion of the acquisition of Alpha Mind Technology Limited and the termination of the Lianlian buyout. On November 22, the company penned an equity. Full story available on Benzinga.com

Alpha 52
article thumbnail

Weekly Roundup: February 2-8, 2024

Harvard Corporate Governance

Skiadopoulos (Queen Mary University of London and the University of Piraeus), on Thursday, February 8, 2024 Tags: ESG , ESG alpha , SASB , Stock performance , Sustainability Accounting Standards Board Global Proxy Voting Policy for Vanguard-advised funds Posted by John Galloway, Vanguard, Inc., Langston and Kyle A.

Alpha 100
article thumbnail

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Benzinga

Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., Chairman, Peak Bio, and Ray Prudo, M.D. Chairman, Akari Therapeutics.

article thumbnail

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Benzinga

Key highlights of the merger include: Peak's innovative ADC toolkit and lead program The merged pipeline features a robust ADC toolkit with novel payload and linker technologies. Peak Bio's Phase 2-ready PHP-303 program is targeting alpha-1 antitrypsin deficiency (AATD).

Alpha 40
article thumbnail

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Benzinga

Key highlights of the merger include: Peak's innovative ADC toolkit and lead program The merged pipeline features a robust ADC toolkit with novel payload and linker technologies. Peak Bio's Phase 2-ready PHP-303 program is targeting alpha-1 antitrypsin deficiency (AATD).

Alpha 40